Ask which product and which use
A research compound, a named prescription medicine and a finished cosmetic formulation are not interchangeable categories. Do not transfer the status of one product to another solely because both mention a related molecule.
A useful status entry identifies the responsible regulator, named finished product, formulation, relevant indication and source document. It also records when that document was checked.
A narrow example from tesamorelin
The inspected EGRIFTA WR label provides a product-specific context for excess abdominal fat in adults with HIV-associated lipodystrophy and states that it is not indicated for weight-loss management.
This is a description of that document, not a claim that every tesamorelin material is an approved medicine. A supplier's research vial does not inherit a finished product's labeling by sharing a molecule name.
Use the appropriate official record
Use Drugs@FDA for relevant US approval documents and EMA's medicines information for the records it publishes. Jurisdictions and publication systems differ; a result in one is not a universal global status.
A ClinicalTrials.gov record establishes that a study record exists, not that a regulator has approved the intervention. A journal article and a laboratory certificate are also different document types.
A status entry that can be audited
Record exactly what the source says and avoid substituting broad labels such as approved peptide for a precise product statement.
- Named product and formulation.
- Jurisdiction and responsible regulator.
- Document title, version or publication date.
- Indication or other specific scope.
- Date checked and unresolved questions.